96. Crohn disease Clinical trials / Disease details
Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05049525 (ClinicalTrials.gov) | February 22, 2022 | 25/8/2021 | Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease | Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease Not Responding Adequately to Current Therapy | Crohn's Disease;Inflammatory Bowel Diseases | Drug: Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally.;Drug: Itraconazole's matching placebo 400 mg/day and terbinafine's matching placebo 500 mg/day administered orally. | Montreal Heart Institute | NULL | Recruiting | 18 Years | 65 Years | All | 68 | Phase 2 | Canada |